Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
about
New treatments for cocaine dependence: a focused reviewNew developments in the pharmacotherapy of cocaine abuseThe role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Associations of glutamate decarboxylase genes with initial sensitivity and age-at-onset of alcohol dependence in the Irish Affected Sib Pair Study of Alcohol Dependence.The role of acetylcholine in cocaine addiction.Baclofen has opposite effects on escalation of cocaine self-administration: increased intake in rats selectively bred for high (HiS) saccharin intake and decreased intake in those selected for low (LoS) saccharin intake.Reinstatement of methamphetamine seeking in male and female rats treated with modafinil and allopregnanolone.Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in ratsGuanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individualsDysbalance of cortical inhibition and excitation in abstinent cocaine-dependent patientsBaclofen suppresses binge eating of pure fat but not a sugar-rich or sweet-fat diet.Too much of a good thing: neurobiology of non-homeostatic eating and drug abuseHypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep.The Role of GABAB Receptors in Morphine Self-Administration.Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint?Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.Microdialysis and the neurochemistry of addiction.Use of animal models to develop antiaddiction medications.Astrocytic control of synaptic transmission and plasticity: a target for drugs of abuse?Hypothesis-driven medication discovery for the treatment of psychostimulant addictionCandidate genes for cannabis use disorders: findings, challenges and directionsEvolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse.Targeting GABAB receptors for anti-abuse drug discovery.Differential Control of Cocaine Self-Administration by GABAergic and Glutamatergic CB1 Cannabinoid Receptors.Substance P inhibits GABAB receptor signalling in the ventral tegmental area.Protracted 'pro-addictive' phenotype produced in mice by pre-adolescent phenylpropanolamine.Selective inhibition of M5 muscarinic acetylcholine receptors attenuates cocaine self-administration in rats.Heavy alcohol use in adolescence is associated with altered cortical activity: a combined TMS-EEG study.GABA(B) receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus.Baclofen prevents the elevated plus maze behavior and BDNF expression during naloxone precipitated morphine withdrawal in male and female mice.
P2860
Q28252765-22A1A54B-7789-4730-AF8A-142B6059DE2CQ28302782-C8F7AF95-D7D6-4A80-ACB3-1F9BF642F600Q33598487-075E087A-6B65-4686-87EB-FB35A4E639E2Q33750970-0C4BE6B7-C225-4E61-9268-14A25C982842Q34700186-DA4E95B7-4134-4A61-A4D3-F7061571B7F7Q35508010-59D6CA58-9BAA-4267-B709-D3E820874F05Q35541827-B42757F7-2BDB-4CAF-9BFD-A711B43E0E2DQ35568800-5AF89C88-2EE3-4E8D-8D45-C5591DD5037DQ35608560-B264DEDA-5B04-45DE-B7BD-17506B4551A1Q35690913-1A13F2E8-6CAD-4F16-835B-2832E1233F96Q35795667-15DE638C-44DD-4401-AC3D-FD6A7EC93DD5Q36218822-5E3DBFCA-797E-4B0A-A9A3-F86330BE998BQ36525478-993DC1A7-732F-4EEB-9CC5-9CA21C5C4C34Q36706555-2525AEC8-C7F2-4B15-AAAE-56C7C4EDC2D3Q36900876-CFEF8E11-7C51-470B-AEF4-FFFDC05C1194Q36952858-14EF2FB1-0E15-4708-9AF3-0AAE29173D49Q36967426-FF9A29BD-186D-4FF6-9A65-1930DADDA2F3Q37083099-93EF07FA-26B1-43DB-BE02-528628DD8A17Q37085367-81E5D343-0E5A-450C-8D3D-8F1C01C8C81EQ37183687-B93B81ED-1617-4538-9E66-5653E6DC81F8Q37245382-4D249DDA-C14E-4196-AF4F-31D4C61E72BAQ37855928-6D0C6545-1085-4CB3-BE7B-3C5E4FF5AD8BQ38246629-570309D9-8EA0-4651-9DFF-3FCC8344E362Q42124542-4739C178-F044-4006-A0B5-042BE11384AAQ43128890-6FB6D5EE-B288-478D-BF58-D9B8CCBA7252Q46811620-99D5DC08-A5A8-459F-A9DE-5A15AE89CAC9Q48167663-D24AC8D0-4D7C-40E1-A877-DC55E279F4C5Q48385228-2778FB92-D4BE-4F0D-B57C-A109AF15E007Q48504270-60F9088D-3BBC-4C70-B8CB-95E162B67399Q48961317-C3BC8D0E-96B8-4BF9-A87F-0F088913F7F4
P2860
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@ast
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@en
type
label
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@ast
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@en
prefLabel
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@ast
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@en
P1476
Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.
@en
P2093
David C S Roberts
P356
10.1016/J.PHYSBEH.2005.06.017
P407
P577
2005-09-01T00:00:00Z